<DOC>
	<DOCNO>NCT01704183</DOCNO>
	<brief_summary>The purpose study study effect fingolimod cardiac autonomic regulation patient relapse-remitting multiple sclerosis . This do measure heart rate variability 24-hour Holter record myocardial ventricular repolarisation pattern 12-lead electrocardiogram tracing . The fingolimod treatment prescribe accord accept drug label .</brief_summary>
	<brief_title>Effect Fingolimod Cardiac Autonomic Regulation Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The study include 30 relapse-remitting multiple sclerosis patient . Assessments heart rate variability myocardial ventricular repolarisation pattern do 1 ) fingolimod , 2 ) first day fingolimod 3 ) 3 month use 4 ) 12 month use fingolimod .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Age 18 65 year Understands propose research action take The write informed consent give clinical indication fingolimodtreatment Patient refuse Patient take take part clinical drug trial last month No clinical indication use fingolimod Contraindication use fingolimod</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>relapse-remitting multiple sclerosis</keyword>
	<keyword>heart rate variability</keyword>
	<keyword>fingolimod</keyword>
	<keyword>cardiac autonomic regulation</keyword>
</DOC>